MicroRNA-134 deactivates hepatic stellate cells by targeting TGF-β activated kinase 1-binding protein 1

Area of Science:

• Hepatology
• Molecular Biology
• Biochemistry

Background:

• Aberrant microRNA expression is linked to liver fibrogenesis.
• MicroRNA-134 (miR-134) levels are reduced in liver fibrosis and cancer models.
• Hepatic stellate cells (HSCs) are key drivers of liver fibrosis.

Purpose of the Study:

• To investigate the role and mechanisms of miR-134 in hepatic fibrosis.
• To determine if miR-134 regulates HSC activation and fibrogenic gene expression.
• To identify the molecular targets of miR-134 in HSCs.

Main Methods:

• miR-134 expression analysis in various rat liver fibrosis models and activated HSCs.
• In vitro studies assessing the effects of miR-134 mimics and inhibitors on HSC proliferation and fibrogenic markers (alpha-SMA, Collagen I).
• Luciferase reporter assays and Western blotting to confirm direct binding of miR-134 to TAB1 3' UTR and assess TAB1 expression.
• TAB1 knockdown experiments in HSCs.

Main Results:

• miR-134 expression was significantly decreased in multiple models of liver fibrosis and in activated HSCs.
• Overexpression of miR-134 suppressed HSC proliferation and reduced alpha-SMA and Collagen I expression, while miR-134 inhibition promoted HSC activation.
• miR-134 directly targets the 3' UTR of transforming growth factor-β-activated kinase 1-binding protein 1 (TAB1), reducing its expression in HSCs.
• TAB1 expression was elevated in fibrotic livers and activated HSCs, and TAB1 knockdown mimicked miR-134's antifibrotic effects.

Conclusions:

• miR-134 acts as a tumor suppressor in liver fibrosis by inhibiting HSC activation through direct targeting of TAB1.
• Restoring miR-134 levels or inhibiting TAB1 presents a promising therapeutic strategy for liver fibrosis.